Evan David Seigerman
Stock Analyst at BMO Capital
(3.29)
# 1,052
Out of 5,138 analysts
54
Total ratings
48.94%
Success rate
4.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Upgrades: Outperform | $82 → $130 | $109.45 | +18.78% | 5 | Dec 18, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $725 → $850 | $733.78 | +15.84% | 9 | Dec 4, 2025 | |
| AMGN Amgen | Maintains: Outperform | $335 → $372 | $331.00 | +12.39% | 5 | Dec 3, 2025 | |
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $46 | $60.68 | -24.19% | 8 | Nov 25, 2025 | |
| REPL Replimune Group | Upgrades: Market Perform | $2 → $11 | $7.01 | +56.92% | 5 | Nov 3, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $214.04 | +12.13% | 8 | Sep 12, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $17.52 | +48.40% | 2 | Jun 12, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $26.29 | +6.50% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $12.03 | -16.87% | 1 | May 5, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $70 → $112 | $74.00 | +51.35% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $91.02 | +9.87% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $25.52 | +41.07% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.92 | -49.32% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $1,041.29 | -61.97% | 1 | Sep 6, 2022 |
Merck & Co.
Dec 18, 2025
Upgrades: Outperform
Price Target: $82 → $130
Current: $109.45
Upside: +18.78%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Outperform
Price Target: $725 → $850
Current: $733.78
Upside: +15.84%
Amgen
Dec 3, 2025
Maintains: Outperform
Price Target: $335 → $372
Current: $331.00
Upside: +12.39%
Novo Nordisk
Nov 25, 2025
Maintains: Market Perform
Price Target: $50 → $46
Current: $60.68
Upside: -24.19%
Replimune Group
Nov 3, 2025
Upgrades: Market Perform
Price Target: $2 → $11
Current: $7.01
Upside: +56.92%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $214.04
Upside: +12.13%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $17.52
Upside: +48.40%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $26.29
Upside: +6.50%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $12.03
Upside: -16.87%
Disc Medicine
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $74.00
Upside: +51.35%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $91.02
Upside: +9.87%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $25.52
Upside: +41.07%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.92
Upside: -49.32%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $1,041.29
Upside: -61.97%